EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Poll|July 25, 2014
Rash in an Immunocompromised Man: Your Dx?
This man had been taking vancomycin and piperacillin/tazobactam for 3 weeks for osteomyelitis. What does the rash look like to you?
Advertisement
A 78-year-old man had a rash for 5 days and dyspnea for 2-weeks; he also had a cough with white sputum and occasional fever without chills. He had hypertension, T2 diabetes, and mantle cell lymphoma after splenectomy. He started taking vancomycin and piperacillin/tazobactam 3 weeks earlier for osteomyelitis.
What does this look like to you?
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
Capsule-Sponge Testing Could Help Close the Barrett’s Screening Gap: An Expert Q&A
2
Elinzanetant Linked to Broad Improvements in Sleep Disturbance in Women With Moderate-to-Severe Vasomotor Symptoms
3
AI-Enhanced Virtual Reality Program Delivering CBT Shows Early Feasibility for Menopause Symptoms: TMS 2026
4
Long-Acting Injectable HIV PrEP: Efficacy, Safety, and Injection Reactions
5